Abstract
Hsp90 is a potential target for the treatment of cancer. Curcumin is a natural product used to prevent and treat cancer. 4-(4-Hydroxy-3-methoxybenzyl) curcumin (C086), a 4-arylmethyl curcumin analogue, showed lead-like properties. Western blot analyses and molecular docking study supported C086 as an Hsp90 inhibitor. Subsequently, C086 analogues were designed, synthesized and evaluated. These compounds showed increased antiproliferative activity against SKBr3 and MCF-7 breast cancer cells. The most promising compounds 7 and 10 (IC50=1.66µM and 0.509µM) were 5- fold and 17-fold better than C086 (IC50=8.55µM) against SkBr3 cell, respectively. Her2 degradation and Hsp70 induction were observed upon administration of selected 4-arylmethyl curcumin analgues, suggesting that these compounds exerted their activity through Hsp90 inhibition.
Keywords: 4-Arylmethyl curcumin analogue, Breast cancer, Curcumin, Hsp90, Hsp90 inhibitors, Molecular docking.
Letters in Drug Design & Discovery
Title:Synthesis and Evaluation of 4-arylmethyl Curcumin Analgues as Potent Hsp90 Inhibitors
Volume: 11 Issue: 8
Author(s): Yang Liu, Min Ye, Qundan Wu, Lixian Wu and Jianhua Xu
Affiliation:
Keywords: 4-Arylmethyl curcumin analogue, Breast cancer, Curcumin, Hsp90, Hsp90 inhibitors, Molecular docking.
Abstract: Hsp90 is a potential target for the treatment of cancer. Curcumin is a natural product used to prevent and treat cancer. 4-(4-Hydroxy-3-methoxybenzyl) curcumin (C086), a 4-arylmethyl curcumin analogue, showed lead-like properties. Western blot analyses and molecular docking study supported C086 as an Hsp90 inhibitor. Subsequently, C086 analogues were designed, synthesized and evaluated. These compounds showed increased antiproliferative activity against SKBr3 and MCF-7 breast cancer cells. The most promising compounds 7 and 10 (IC50=1.66µM and 0.509µM) were 5- fold and 17-fold better than C086 (IC50=8.55µM) against SkBr3 cell, respectively. Her2 degradation and Hsp70 induction were observed upon administration of selected 4-arylmethyl curcumin analgues, suggesting that these compounds exerted their activity through Hsp90 inhibition.
Export Options
About this article
Cite this article as:
Liu Yang, Ye Min, Wu Qundan, Wu Lixian and Xu Jianhua, Synthesis and Evaluation of 4-arylmethyl Curcumin Analgues as Potent Hsp90 Inhibitors, Letters in Drug Design & Discovery 2014; 11 (8) . https://dx.doi.org/10.2174/1570180811666140512221037
DOI https://dx.doi.org/10.2174/1570180811666140512221037 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Italian Association of Clinical Endocrinologists (AME) and Italian AACE Chapter Position Statement for Clinical Practice: Assessment of Response to Treatment and Follow-Up in Gastroenteropancreatic Neuroendocrine Neoplasms
Endocrine, Metabolic & Immune Disorders - Drug Targets Role of NF-κB in the Regulation of Cytochrome P450 Enzymes
Current Drug Metabolism Mesenchymal Stromal Cells; Role in Tissue Repair, Drug Discovery and Immune Modulation
Current Drug Delivery Preface
Current Pharmaceutical Design Targeted Radionuclide Therapy - An Overview
Current Radiopharmaceuticals A Role for the Inflammatory Mediators Cox-2 and Metalloproteinases in Cancer Stemness
Anti-Cancer Agents in Medicinal Chemistry Polyphenols and Cardiovascular Disease: A Critical Summary of the Evidence
Mini-Reviews in Medicinal Chemistry T-Cell Zeta Chain Expression, Phosphorylation and Degradation and their Role in T-Cell Signal Transduction and Immune Response Regulation in Health And Disease
Current Signal Transduction Therapy Hematological Malignancies and Pregnancy. A Brief Review
Reviews on Recent Clinical Trials Meta-analysis of NFKB1-94 ATTG Ins/Del Polymorphism and Risk of Breast Cancer
Current Drug Metabolism Clinical Uses of Melatonin: Evaluation of Human Trials
Current Medicinal Chemistry A Wnt-ow of Opportunity: Targeting the Wnt/β-Catenin Pathway in Breast Cancer
Current Drug Targets Biopharmaceutics and Therapeutic Potential of Engineered Nanomaterials
Current Drug Metabolism A Review on PARP1 Inhibitors: Pharmacophore Modeling, Virtual and Biological Screening Studies to Identify Novel PARP1 Inhibitors
Current Topics in Medicinal Chemistry Application of Reproductive Hormone Peptides for Tumor Targeting
Current Pharmaceutical Biotechnology OX40 and OX40L Interaction in Cancer
Current Medicinal Chemistry Editorial (Thematic Issue: Vaccines)
Recent Patents on Inflammation & Allergy Drug Discovery Lycopene Protects Liver Against Ulcerative Colitis
Current Drug Therapy Glucose Blood Levels as a Therapeutic Target in Acute Ischaemic Stroke Setting
Current Topics in Medicinal Chemistry Synthesis and Molecular Docking of New Thiophene Derivatives as Lactate Dehydrogenase-A Inhibitors
Mini-Reviews in Medicinal Chemistry